# Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

> **NCT01416428** · PHASE1,PHASE2 · TERMINATED · sponsor: **Amgen** · enrollment: 210 (actual)

## Conditions studied

- Multiple Myeloma
- Waldenstrom Macroglobulinemia

## Interventions

- **DRUG:** oprozomib

## Key facts

- **NCT ID:** NCT01416428
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-10-15
- **Primary completion:** 2016-08-08
- **Final completion:** 2019-08-12
- **Target enrollment:** 210 (ACTUAL)
- **Why stopped:** A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in 2011-001 was halted.
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416428, "Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01416428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*